Pathogens distribution and risk factors of pulmonary infection in elderly patients with acute exacerbation of chronic obstructive pulmonary disease

Abstract

Abstract:

Objective To investigate the distribution of pathogens and risk factors of acute exacerbation of chronic obstructive pulmonary disease (COPD) in elderly patients with pulmonary infection. Methods Two hundred and sixty elderly patients with acute exacerbation of chronic obstructive pulmonary disease in our hospital were selected. All patients were divided into infection group and non-infection group accorded to the occurrence of pulmonary infection. The clinical data of all cases were recorded, and the pulmonary infection patients were given analysis of the risk factors and the pathogens distribution. Results There were 30 patients of pulmonary infection in the 260 patients (11.5%). In the infection group, a total of 45 strains of pathogen including 25 strains of gram negative bacteria, 18 strains of gram positive bacteria, 2 strains of candida spp. were isolated. The top 4 pathogens were Pseudomonas aeruginosa, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus etc. The Pseudomonas aeruginosa, Klebsiella pneumoniae had relatively high rate of resistance to erythromycin, gentamicin, and the Pseudomonas aeruginosa, Staphylococcus aureus had relatively high rate of levofloxacin and meropenem. Univariate regression analysis showed that the history of diabetes, smoking, long-term use of antibiotics, long-term use of hormones, long-term bed were significant different in the infection group and in non-infection group (P<0.05); Non conditional Logistic regression analysis showed that the diabetes (OR=10.593, P=0.000), smoking (OR=6.194, P=0.008), long-term use of antibiotics (OR=3.255, P=0.014) were the risk factors of pulmonary infection (P<0.05). Conclusion Pulmonary infection was common in acute exacerbation of chronic obstructive pulmonary disease, Gram-negative bacteria might be the main pathogen. Diabetes, smoking, long-term use of antibiotics were the risk factors of pulmonary infection.

Key words: elderly, chronic obstructive pulmonary disease, pulmonary infection, high risk factors, pathogenic bacteria

CLC Number:

R563.1

WEI Yong-gang, YAN Hong-ying, XIAO Yuan-hong. Pathogens distribution and risk factors of pulmonary infection in elderly patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Chinese Journal of Mycology, 2018, 13(3): 177-180,183.

References

[1] VogelmeierC, FabbriLM, RabeKF, et al. Effect of tiotropium vs. salmeterol on exacerbations:GOLD Ⅱ and maintenance therapy naive patients[J]. Respir Med, 2013, 107(1):75-83.
[2] FinneyL, BerryM, SinganayagamA, et al. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease[J]. The Lancet Respiratory Medicine, 2014, 2(11):919-932.
[3] 罗兴文,魏龙.慢性阻塞性肺疾病患者医院肺部感染的相关危险因素分析[J].新疆医学,2016,46(1):39-41.
[4] 刘永娟,戚明,门浩,等.慢性阻塞性肺疾病患者肺部真菌感染与耐药性研究[J].中华医院感染学杂志,2016,21(3):578-579.
[5] Porto BN, Stein RT. Neutrophil Extracellular Traps in Pulmonary Diseases:Too Much of a Good Thing[J].Front Immunol,2016,15(7):311-319.
[6] Capistrano SJ, Zakarya R, Chen H, et al. Biomass Smoke Exposure Enhances Rhinovirus-Induced Inflammation in Primary Lung Fibroblasts[J].Int J Mol Sci,2016,17(9):64-71.
[7] HerathS, PooleP. Prophylactic antibiotic therapy in chronic obstructive pulmonary disease[J]. JAMA,2014, 311(21):2225.
[8] LoukidesS, BartziokasK, VestboJ, et al. Novel anti-inflammatory agents in COPD:targeting lung and systemic inflammation[J]. Curr Drug Targets, 2013, 14(2):235-245.
[9] Zhang JC, Chen G, Chen L, et al. TGF-β/BAMBI pathway dysfunction contributes to peripheral Th17/Treg imbalance in chronic obstructive pulmonary disease[J].Sci Rep,2016,23(6):1911-1918.
[10] Ehrmann E, Jolivet-Gougeon A, Bonnaure-Mallet M, et al. Multidrug-resistant oral Capnocytophaga gingivalis responsible for an acute exacerbation of chronic obstructive pulmonary disease:Case report and literature review[J].Anaerobe,2016,13(42):50-54.
[11] 胡俊芳,罗敏,王挺.慢性阻塞性肺疾病下呼吸道感染病原学分析及抗生素选择[J].西部医学,2016,28(1):74-76,83.
[12] CrinerGJ, ConnettJE, AaronSD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD[J]. N Engl J Med, 2014, 370(23):2201-2210.
[13] Aleva FE, Voets LW, Simons SO, et al.Prevalence and Localization of Pulmonary Embolism in Unexplained Acute Exacerbations of COPD:A systematic review and meta-analysis[J].Chest,2016,92(16):752-760.
[14] Chen HF, Homan S, Carlson E, et al. The Impact of Race and Neighborhood Racial Composition on Preventable Readmissions for Diabetic Medicare Home Health Beneficiaries[J].J Racial Ethn Health Disparities,2016,8(11):389-392.
[15] Duell BL, Su YC, Riesbeck K. Host-pathogen interactions of nontypeable Haemophilus influenzae:from commensal to pathogen[J].FEBS Lett,2016,8(10):518-522.
[16] Scannapieco FA, Cantos A. Oral inflammation and infection, and chronic medical diseases:implications for the elderly[J].Periodontol,2016,72(1):153-175.
[17] Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON):a randomised, double-blind placebo-controlled trial[J]. Lancet Respir Med, 2014, 2(3):187-194.
[18] Huang JT, Bolton CE, Miller BE, et al. Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease[J].Eur Respir J,2016,9(1):547-552.
[19] Kim JH, Park S, Hwang YI, et al.Immunoglobulin G Subclass Deficiencies in Adult Patients with Chronic Airway Diseases[J].J Korean Med Sci,2016,31(10):1560-1565.
[20] Kim RY, Rae B, Neal R, et al. Elucidating novel disease mechanisms in severe asthma[J].Clin Transl Immunology,2016,5(7):91-98.